Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Placebo-controlled, Randomized, Observer-blinded, Multi-center Study to Assess the Safety, Reactogenicity, and Immunogenicity of Booster Vaccination of A SARS-CoV-2 Recombinant Protein Nanoparticle Vaccine (GBP510)

NCT05175950 is registered in ClinicalTrials.gov with Korea University Guro Hospital as lead sponsor.

NCT NCT05175950
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05175950 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Placebo-controlled, Randomized, Observer-blinded, Multi-center Study to Assess the Safety, Reactogenicity, and Immunogenicity of Booster Vaccination of A SARS-CoV-2 Recombinant Protein Nanoparticle Vaccine (GBP510)
Lead sponsor
Korea University Guro Hospital
Phase
Phase 2
Overall status
Unknown status
Start date
January 24, 2022
Completion date
November 30, 2023
Enrollment
770 (estimated)
Sites
9

Conditions

As the registry lists them; a condition with its own page is linked.

covid-19 (healthy volunteers)